Daily Chart: Inovio joins COVID-19 vaccine developers showing mouse immunogenicity data
Inovio reported mouse immunogenicity data from its COVID-19 vaccine that include lung detection of anti-SARS-CoV-2 antibodies, hinting at protectiveness. While direct comparison to mouse data from other COVID-19 vaccines is difficult, the findings put the Inovio vaccine roughly on par with University of Oxford’s.
Inovio Pharmaceuticals Inc. (NASDAQ:INO), which gained $1.23 to $15.79 Wednesday, reported in Nature Communications that a single administration of INO-4800 induced serum anti-spike antibody titers of about 2,000 in mice. Two immunizations resulted in serum neutralizing titers of 128.
In guinea pigs, a single immunization -- at a dose four times that given to mice -- led to total serum titers of 10,530, and three vaccinations induced neutralizing titers >320.
Bronchoalveolar lavage fluid from vaccinated mice and guinea pigs had anti-spike titers of about 100.
The company expects to have data from challenge studies in multiple animal models in the coming weeks, as well as preliminary Phase I data for INO-4800 next month. It plans to start a Phase II/III trial in July or August.
Inovio joins at least four other groups -- the University of Oxford and partner Vaccitech Ltd.; Sinovac Biotech Ltd. (NASDAQ:SVA); the University of Pittsburgh; and Moderna Inc. (NASDAQ:MRNA) -- to announce successful induction of anti-spike antibodies in mice.
Of the five teams, only Inovio, Oxford and Sinovac have reported antibody titers.
Moderna has not released detailed preclinical data from its candidate mRNA-1273, but the company announced Monday that the vaccine induced neutralizing antibodies in humans (see “What Moderna’s COVID-19 Vaccine Data Do Not Say”).